Gcg Share · KR7340450006 (XKOS) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

GC Genome Corporation operates as a clinical genome analysis company in South Korea. It offers hereditary cancer, tissue and liquid biopsy genetic, blood cancer, and homologous recombination deficiency tests under the Green Plan names; Guardant360, a blood genetic profiling test; Guardant Reveal, a liquid biopsy microscopic residual disease detection and recurrence monitoring test; and genetic rare disease testing services for chromosomal microarray, targeted exome sequencing, whole exome sequencing, and diagnostic genome sequencing. The company also provides ai-CANCERCH, an AI algorithm-based multi-cancer early screening test; Jins Sketch, a genetic test for personalized nutrition; Genome Health and Risk Screen that identifies various disease-susceptibility genes; Green Biome for human symbiotic microorganism genetic analysis service; Genome Screen, an optimal genetic test for preemptive action; Telorisk, an indicator of biological age; and drug compatibility DNA test. In addition, it offers G-NIPT, a noninvasive fetal chromosomal abnormality screening test; Prenatal CMA, a diagnostic test for fetal chromosomal abnormalities with higher diagnostic value; i-screen for newborn genetic screening; and dd-cfDNA, a single nucleotide polymorphism test of cell-free nucleic acid derived from organ transplant donors. The company was founded in 2013 and is based in Yongin-si, South Korea.